Human CD20 Antibody - Obinutuzumab IgG1 Isotype

Anti-human CD20 antibody - Human IgG1 (high effector functions)

Anti-hCD20-Ga-hIgG1 is an Obinutuzumab biosimilar with an IgG1 isotype. Obinutuzumab, formerly named Afutuzumab or GA101, targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes.

InvivoGen’s Anti-hCD20-Ga-hIgG1 comprises the variable region of Obinutuzumab and a human IgG1 constant region for high effector functions.
More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see below or in the 'upon request' section).
InvivoGen also provides type I anti-hCD20 mAbs featuring the variable regions of Rituximab or Ofatumumab, with either native or engineered Fc regions.

Key features

• Each lot is functionally tested and validated
• The complete sequence of the antibody construct has been verified
• Absence of endotoxins determined by the EndotoxDetect™ assay

Background

Obinutuzumab is a type II (second-generation) non-fucosylated, fully humanized IgG1 monoclonal antibody (mAb) with improved therapeutic efficacy compared to previously developed type I (first-generation) anti-hCD20 mAbs, such as Rituximab and Ofatumumab. Obinutuzumab has been approved by the FDA to treat chronic lymphocytic leukemia (CLL) [1-3].

Read our review on Antibody Isotypes

References:

1. Gagez AL. & Cartron G., 2014. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 26(5):484-91.
2. Smolej L., 2014. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. Pharmgenomics Pers Med. 8:1-7.
3. Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306.